Dr. Joy Cote from Prelude Therapeutics, LLC. will present
Advancing Drug Discovery: A Screening Approach Integrating Fragment-Based Strategies for Targeting KAT6
A screening-focused approach to drug discovery emphasizing the critical aspects of assay development, including high-throughput screening methodologies, in vitro techniques, and robust validation criteria to ensure reproducibility and accuracy. Focusing on fragment-based drug discovery (FBDD), a method that leverages small molecular fragments to identify novel compounds with specificity toward biological targets. This work underscores the potential of templated FBDD strategies to exploit chemical space effectively, enabling the discovery of novel, selective modulators for conserved targets within the MYST family of acetyltransferases. Highlighting the strategic integration of biology, chemistry, and advanced screening methodologies to enable the discovery of innovative therapeutic candidates.
Friday, December 6th, 2024, 3:30 PM, SC 160Potsdam Campus
Zoom Information: Link
Meeting ID: 950 1099 7564
Passcode: chemistry